U.S. Markets closed
  • S&P Futures

    3,827.75
    +2.25 (+0.06%)
     
  • Dow Futures

    30,956.00
    +23.00 (+0.07%)
     
  • Nasdaq Futures

    11,683.00
    +8.75 (+0.07%)
     
  • Russell 2000 Futures

    1,739.20
    +0.90 (+0.05%)
     
  • Crude Oil

    111.45
    -0.31 (-0.28%)
     
  • Gold

    1,823.40
    +2.20 (+0.12%)
     
  • Silver

    20.80
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0533
    +0.0008 (+0.0737%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2204
    +0.0020 (+0.1611%)
     
  • USD/JPY

    136.0410
    -0.0870 (-0.0639%)
     
  • BTC-USD

    20,352.99
    -309.01 (-1.50%)
     
  • CMC Crypto 200

    441.21
    -8.86 (-1.97%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,810.39
    -239.08 (-0.88%)
     

Agenus to Participate at Jefferies Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Agenus Inc.
Agenus Inc.

LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and CEO of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:30 AM EST. The Conference will be held at the New York Marriott Marquis from June 8th – 10th, during which Agenus will host one-on-one meetings with investors.

A webcast/replay will be available for 90 days after completion of the fireside chat and may be accessed via https://wsw.com/webcast/jeff240/agen/1816875 or on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact

Ethan Lovell
339-927-1763
ethan.lovell@agenusbio.com